✦ LIBER ✦

A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies

✍ Scribed by Ana Maria Lopez; Marsha Ketchum; Heather Nichols; Min-Jian Xu; Yei-Mei Peng; Robert Dorr; David S. Alberts

Book ID: 105993848
Publisher: Springer
Year: 2000
Tongue: English
Weight: 74 KB
Volume: 46
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800000154

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of high-dose infusional hy

Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-α-2a in patients with advanced malignancies

✍ Scott Wadler; Hilda Haynes; Richard Schechner; Alla Rozenblit; Peter H. Wiemik 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 547 KB

Age-stratified phase I trial of a combin

Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

✍ G. S. Falchook; M. Duvic; D. S. Hong; J. Wheler; A. Naing; J. Lim; R. Kurzrock 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 507 KB

Phase II trial of dose-dense doxorubicin

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function

✍ Matthew D. Galsky; Alexia Iasonos; Svetlana Mironov; Joseph Scattergood; Mary G. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

Sunitinib combined with pemetrexed and c

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

✍ Blais, Normand; Camidge, D. Ross; Jonker, Derek J.; Soulières, Denis; Laurie, Sc 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 253 KB

A phase I study of liposome-encapsulated

A phase I study of liposome-encapsulated doxorubicin (D-99) and granulocyte colony stimulating factor (G-CSF) in patients with advanced solid tumors

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 175 KB

A phase I trial of KX2-391, a novel non-

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

✍ Aung Naing, Roger Cohen, Grace K. Dy, David S. Hong, Lyn Dyster, David G. Hangau 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 144 KB